Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2005

View Archived Issues

FX-06 cleared to begin clinical trials

Renoprotective effects of pyridavone

Preclinical profile of a nonhormonal therapy for postmenopausal syndromes

StaphVAX reduces risk of recurrent bacteremia in hemodialysis patients

SPIRIT II study of Xience V stent completes enrollment

Orphan drug designation for Coramsine for metastatic renal cell carcinoma

Recent agreement validates Oradur technology

Altachem Pharma changes name to Quest PharmaTech

Enrollment under way in phase III Amoxicillin PULSYS trial

ARIES-1 study of ambrisentan achieves enrollment target

Shire relates Q3 developments

Anti-HBV siRNAs effectively lower HBV DNA levels in vivo

In vivo neuroprotective effects of NNZ-2566

Analgesic properties of a novel antagonistic anti-TrkA monoclonal antibody

TSP-2 gene therapy prevents TSP-1-mediated fibrogenesis in a diabetic nephropathy model

A2A receptor agonists ameliorate renal NO production in diabetic nephropathy in rats

SEW-2871: An S1P1 receptor agonist with renoprotective actions in vivo

Sildenafil improves performance in rodent models of cognitive decline

OSI completes acquisition of Eyetech

Update on the long-term safety of lanthanum carbonate in dialysis patients

NCX-4016 fails to meet primary endpoint in phase II study in PAOD patients

Good safety profile reported for single-dose ACP-104 in patients with schizophrenia

Trinam reported safe in hemodialysis patients

Promising results with Oxxon's specific prime/boost therapy for chronic hepatitis B

Novel antiinfective agents disclosed in recent patent literature

Agents for metabolic disorders prepared and tested

Recent Bristol-Myers Squibb patent claims compounds with potential for thrombotic disorders

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....